San Diego-based Viking Therapeutics marked itself as a significant competitor in the weight loss drug sector in February soon after revealing promising details from the mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when provided being a weekly injection and in March the company unvei